Supplemental material
Report
Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity
, , , , , , , 
, , , & show all
Torsten HanekeAffimed GmbH, Research Department, Heidelberg, Germanyhttp://orcid.org/0000-0003-2563-1055
http://orcid.org/0000-0003-2563-1055, , , & show allRelated Research Data
A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.
Source:
American Society of Hematology
Bispecific antibodies: design, therapy, perspectives
Source:
Informa UK Limited
Crystal structures of mono- and bi-specific diabodies and reduction of their structural flexibility by introduction of disulfide bridges at the Fv interface.
Source:
Springer Science and Business Media LLC
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
Source:
Elsevier BV
Targeting Cancer Stem Cells with Natural Killer Cell Immunotherapy.
Source:
Informa UK Limited
A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies
Source:
American Society of Hematology
A Bispecific Diabody That Mediates Natural Killer Cell Cytotoxicity Against Xenotransplantated Human Hodgkin’s Tumors
Source:
American Society of Hematology
Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity
Source:
American Society for Biochemistry & Molecular Biology (ASBMB)
Macrophages are critical effectors of antibody therapies for cancer
Source:
Informa UK Limited
Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent
Source:
Proceedings of the National Academy of Sciences
:{unav)
Source:
Wiley
Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients
Source:
Elsevier BV
Bispecific T-cell engaging antibodies for cancer therapy.
Source:
American Association for Cancer Research (AACR)
Design and production of novel tetravalent bispecific antibodies
Source:
Springer Science and Business Media LLC
IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
Source:
American Association for Cancer Research (AACR)
Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population
Source:
Elsevier BV
Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity.
Source:
Korean Cancer Association
Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma
Source:
American Society of Clinical Oncology (ASCO)
Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia.
Source:
American Society of Hematology
A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19+ tumor cells
Source:
Informa UK Limited
FcγRIIIa-158V/F Polymorphism Influences the Binding of IgG by Natural Killer Cell FcγRIIIa, Independently of the FcγRIIIa-48L/R/H Phenotype
Source:
American Society of Hematology
Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells.
Source:
Oxford University Press (OUP)
Pharmacokinetic properties of IgG and various Fc fusion proteins in mice.
Source:
Informa UK Limited
Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients
Source:
Springer Science and Business Media LLC
Prognostic value of tumor infiltrating NK cells and macrophages in stage II+III esophageal cancer patients
Source:
Impact Journals, LLC
Use of an anti-CD16 antibody for in vivo depletion of natural killer cells in rhesus macaques
Source:
Wiley
Antibody isotype-specific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapy
Source:
Rockefeller University Press
Bispecific antibodies in cancer immunotherapy.
Source:
SAGE Publications
NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma.
Source:
Oxford University Press (OUP)
A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells
Source:
Informa UK Limited
Bispezifische Antikörper
Source:
Elsevier BV
The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms.
Source:
Informa UK Limited
Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy.
Source:
S. Karger AG
GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.
Source:
American Association for Cancer Research (AACR)
Tumor mutational burden is a determinant of immune-mediated survival in breast cancer
Source:
(:unav)
The making of bispecific antibodies
Source:
Taylor & Francis
Linking provided by
